Skip to main navigation Skip to search Skip to main content

A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once Daily in Treatment- Naive HIV-1 Infected Subjects

University at Buffalo

Project: Research

Project Details

StatusFinished
Effective start/end date08/6/15 → 08/5/20

Funding

  • Merck Sharp and Dohme Limited Liability Corporation: $86,221.31